Cardio-specific Long-term Gene Expression in a Porcine Model After Selective Pressure-regulated Retroinfusion of Adeno-associated Viral (AAV) Vectors
Overview
Authors
Affiliations
Cornerstone for an efficient cardiac gene therapy is the need for a vector system, which enables selective and long-term expression of the gene of interest. In rodent animal models adeno-associated viral (AAV) vectors like AAV-6 have been shown to efficiently transduce cardiomyocytes. However, since significant species-dependent differences in transduction characteristics exist, large animal models are of imminent need for preclinical evaluations. We compared gene transfer efficiencies of AAV-6 and heparin binding site-deleted AAV-2 vectors in a porcine model. Application of the AAVs was performed by pressure-regulated retroinfusion of the anterior interventricular cardiac vein, which has been previously shown to efficiently deliver genes to the myocardium (3.5 x 10(10) viral genomes per animal; n=5 animals per group). All vectors harbored a luciferase reporter gene under control of a cytomegalovirus (CMV)-enhanced 1.5 kb rat myosin light chain promoter (CMV-MLC2v). Expression levels were evaluated 4 weeks after gene transfer by determining luciferase activities. To rule out a systemic spillover peripheral tissue was analyzed by PCR for the presence of vector genomes. Selective retroinfusion of AAV serotype 6 vectors into the anterior cardiac vein substantially increased reporter gene expression in the targeted distal left anterior descending (LAD) territory (65 943+/-31 122 vs control territory 294+/-69, P<0.05). Retroinfusion of AAV-2 vectors showed lower transgene expression, which could be increased with coadministration of recombinant human vascular endothelial growth factor (1365+/-707 no vascular endothelial growth factor (VEGF) vs 38 760+/-2448 with VEGF, P<0.05). Significant transgene expression was not detected in other organs than the heart, although vector genomes were detected also in the lung and liver. Thus, selective retroinfusion of AAV-6 into the coronary vein led to efficient long-term myocardial reporter gene expression in the targeted LAD area of the porcine heart. Coapplication of VEGF significantly increased transduction efficiency of AAV-2.
Structural basis for nuclear import of adeno-associated virus serotype 6 capsid protein.
Hoad M, Nematollahzadeh S, Petersen G, Roby J, Alvisi G, Forwood J J Virol. 2024; 99(1):e0134524.
PMID: 39692478 PMC: 11784021. DOI: 10.1128/jvi.01345-24.
Mazurek R, Tharakan S, Mavropoulos S, Singleton D, Bikou O, Sakata T Nat Commun. 2024; 15(1):10450.
PMID: 39617804 PMC: 11609281. DOI: 10.1038/s41467-024-54635-x.
AAV Capsid Screening for Translational Pig Research Using a Mouse Xenograft Liver Model.
Willimann M, Tiyaboonchai A, Adachi K, Li B, Waldburger L, Nakai H bioRxiv. 2024; .
PMID: 38853940 PMC: 11160762. DOI: 10.1101/2024.05.29.596409.
Transcriptional Targeting Approaches in Cardiac Gene Transfer Using AAV Vectors.
Schroder L, Frank D, Muller O Pathogens. 2023; 12(11).
PMID: 38003766 PMC: 10675517. DOI: 10.3390/pathogens12111301.
Gene therapy during heart perfusion: a new frontier in cardiac regenerative medicine?.
Vervoorn M, Amelink J, Ballan E, Doevendans P, Sluijter J, Mishra M Front Cardiovasc Med. 2023; 10:1264449.
PMID: 37908499 PMC: 10614057. DOI: 10.3389/fcvm.2023.1264449.